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There is increasing evidence for the role of inflammation in schizophrenia, yet the
stability of increased peripheral inflammation in acute psychosis and the degree to
which peripheral inflammation relates to cortical thickness, a measure of the degree
of neuropathology, are unknown. In independent samples, we assessed the peripheral
inflammation marker C-reactive protein (CRP) to determine the extent to which: (1)
CRP was elevated and stable across admissions for acute psychosis, (2) cognition,
daily function and symptom severity are characteristic of chronically ill patients with
schizophrenia displaying elevated CRP, and (3) CRP levels predict cortical thickness.
Study 1 assessed peripheral CRP (primary outcome) and other blood measures
in 174/280 people with acute psychosis while Study 2 assessed peripheral CRP,
cognition and cortical thickness (primary outcomes), symptoms, and daily function in
85/97 chronically ill patients with schizophrenia and 71/87 healthy controls. In acute
psychosis, CRP and neutrophil-to-lymphocyte ratio were significantly elevated relative to
a normal cutoff (with 59.8% of patients having elevated CRP) which remained elevated
across admissions. CRP was significantly elevated in 43% of chronically ill patients
with schizophrenia compared to 20% in controls. Elevated CRP patients displayed
significantly worse working memory and CRP was inversely correlated with cortical
thickness in frontal, insula, and temporal brain regions. This work supports the role of
inflammation in psychotic illnesses and suggests that use of peripheral markers (e.g.,
CRP) in conjunction with diagnosis could be used to identify patients with more cortical
neuropathology and cognitive deficits.
Keywords: schizophrenia, acute psychosis, c-reactive protein, cortical thickness, inflammation, working memory,
cognition, CRP
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INTRODUCTION
Schizophrenia is a severe psychiatric disorder characterized by
positive (e.g., hallucinations and delusions) and negative (e.g.,
lack of motivation) symptoms, cognitive deficits, and functional
decline. Presently there is no inexpensive, easily accessible
diagnostic biomarker for the degree of cortical pathology in
schizophrenia and substantial heterogeneity is associated with
the disorder (1). While there are likely to be multiple causative
pathways for developing schizophrenia (2), there is accumulating
evidence to support the role of inflammation as increasing
risk at least for a subset of patients (3). Therefore, improving
interventions for schizophrenia may depend on identifying
subgroups of patients characterized by inflammatory markers
that can be targeted with specific treatments.
Recently, there has been increasing evidence that
immunological and inflammatory mechanisms may play
important roles in the pathophysiology of schizophrenia
and related psychotic disorders (4–6). Epidemiological
and preclinical evidence implicates prenatal infection and
subsequent immune activation in the etiology of schizophrenia
(7). Autoimmune disorders are significantly more prevalent
in patients with schizophrenia compared to the general
population (8, 9). It has been shown that antipsychotics, the
most common treatment for psychosis, can decrease circulating
levels of inflammatory markers which may, in turn, reduce
psychotic symptoms (10, 11). However, some studies show
an increase in peripheral inflammatory markers with second
generation antipsychotics (12). Results from clinical trials of
anti-inflammatory agents such as aspirin (13), non-steroidal
anti-inflammatory drugs (14), and the microglial inhibitor
minocycline (15, 16) suggest that adjunctive anti-inflammatory
treatments may be a promising therapeutic approach for
reducing symptoms and reversing cognitive deficits in people
with schizophrenia.
Various immune and inflammatory alterations in the brain
and blood have been found in subgroups of people with
schizophrenia, including increased levels of pro-inflammatory
cytokines (17–19), changes in white blood cell count (WBC)
(20), a higher prevalence of positive antinuclear antibodies
(ANA) (21, 22), increased neutrophil-to-lymphocyte ratio (NLR)
(23, 24), and elevated C-reactive protein (CRP) (25, 26).
Increases in inflammatory markers have been shown in subsets
of individuals in both the prodromal stage (27, 28) and first-
episode psychosis (29), suggesting that inflammation is not
secondary to chronic illness or initiation of antipsychotics. The
proportion of chronically ill patients with schizophrenia showing
increased inflammation is generally quite substantial with ∼40%
who display elevated cytokine mRNA in the prefrontal cortex
(17) and ∼40% who display elevated cytokine mRNA in
peripheral blood (30). These findings are consistent with meta-
analytical results showing that cytokines are increased in the
serum of people with schizophrenia (31). Furthermore, elevated
proinflammatory cytokines, e.g., IL-6 and IL-1β, are inversely
related to cognition and frontal brain volume in chronically
ill people with schizophrenia (30). Thus, elevated inflammation
markers appear to be a characteristic of psychosis in a substantial
proportion of patients and they are related to brain structure and
function.
CRP is an acute-phase reactant protein mainly produced
by hepatocytes in response to an increase in circulating pro-
inflammatory cytokines (32). CRP is attractive for use as a
biomarker in psychiatry as it appears to be fairly stable, is
easily and consistently measured by most diagnostic labs, and is
considered a reliable biomarker of systemic inflammation (33–
35). The healthy normal clinical range of CRP levels is generally
< 3 mg/L (36), whilst CRP > 2 mg/L has been associated
with increased risk of cardiovascular disease (37). Recent meta-
analyses have reported a high prevalence of elevated CRP in
schizophrenia (25, 36) and an association between adolescent
CRP and adult schizophrenia diagnosis has been found in a
recent longitudinal study (38). Elevated CRP has been associated
with impaired cognitive functioning in chronically ill patients
with schizophrenia (39, 40) and with acute psychotic episodes
(41). An association between elevated CRP and more severe
psychiatric symptoms in schizophrenia has also been shown
(42); however, other studies have failed to replicate this finding
(40, 43). Other studies suggest that CRP may be particularly
elevated during exacerbations of psychosis (44) andmay decrease
following resolution of an acute psychotic episode (45). Whilst
a small number of studies have shown an association between
elevated CRP and decreased structural brain volume in healthy
older adults (46, 47), there have been no studies to date
assessing the potential link between CRP and cortical thickness
in schizophrenia.
Here, we assess CRP as a marker of inflammation in two
independent samples of patients with psychosis. The aims of
Study 1 were to determine the extent to which: (1) CRP levels
were elevated in a proportion of patients presenting with an acute
psychotic episode, (2) relationships exist between CRP and other
inflammation markers (including NLR, WBC, and ANA), and
(3) peripheral inflammation markers remain stable over repeated
admissions for acute psychotic episodes. We made the following
three hypotheses: (1) CRP would be elevated above 3 mg/L in
a subgroup of patients with acute psychosis, (2) there would
be a significant difference in other peripheral inflammation
markers between patients grouped on the basis of elevated and
normal CRP, and (3) CRP would be consistently elevated during
subsequent admissions for acute psychotic episodes in the same
patients.
Given the limitations of assessing acutely psychotic patients
for brain and cognitive measures, in Study 2 we tested the
extent to which a peripheral inflammation marker (CRP) was
related to cognition and a brain measure (cortical thickness)
in a cohort of chronically ill patients with schizophrenia who
were not acutely psychotic. The aims of Study 2 comparing
chronically ill patients with schizophrenia to a healthy control
group were to determine the extent to which: (1) CRP levels were
elevated, (2) the proportions of patients versus controls having
elevated CRP, (3) there were significant cognitive, symptom
severity, and daily function differences between patients with
elevated and patients with normal CRP levels, and (4) CRP
levels predict cortical thickness. We made the following four
hypotheses: (1) CRPwould be significantly elevated in a subgroup
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of chronically ill patients with schizophrenia and schizoaffective
disorder relative to healthy controls, (2) cognition, symptom
severity, and functional abilities would be significantly affected
in patients with schizophrenia who display elevated CRP relative
to those patients who display normal CRP levels, (3) CRP levels
would negatively correlate with cortical thickness, and (4) CRP
would be elevated to a lesser extent in chronically ill patients
compared to acutely ill patients (comparing results from Study
1 and Study 2).





Participants consisted of patients with an acute psychotic episode
who were admitted to the Mental Health Intensive Care Unit
(MHICU) at the Prince of Wales Hospital, Sydney, Australia,
between March 2013 and February 2016. The MHICU is a 12-
bed inpatient unit that provides treatment for patients who
are acutely and severely mentally ill. A current comprehensive
psychiatric assessment, current physical examination, and the
last 7 days of progress notes were performed/documented prior
to admission. The Prince of Wales Hospital MHICU admission
criteria consisted of the following: (1) the patient is suffering
with a mental disorder or illness which may have complex
comorbidity, (2) the patient is presenting with behavioral
difficulties, which seriously compromise the patient’s physical
wellbeing, psychological wellbeing, the physical wellbeing of
others or the psychological wellbeing of others, (3) the patient’s
risk profile includes some or all of a significant risk of aggression,
absconding with associated serious risk, suicide, or vulnerability,
(4) it has been demonstrated that multidisciplinary management
strategies have not succeeded in containing the presenting
problems in the referringMental Health Service, (5) the patient is
detained under a section of the New South Wales Mental Health
Act (2007), (6) the patient’s risk profile is such that he/she does
not require a higher level of security than that offered by the
MHICU. The MHICU exclusion criteria (categories of patients
who should not be treated on the MHICU) consisted of the
following: (1) patients younger than 18 years, (2) patients older
than 65 years, (3) patients who require a higher level of security
by virtue of the risk profile, (4) patients with a primary diagnosis
of substance misuse, where the current presenting behavior is a
direct result of the substance misuse and not an exacerbation
of a mental illness, (5) patients with a primary diagnosis of a
personality disorder should not routinely be admitted to the
MHICU, (6) patients with a primary diagnosis of dementia, (7)
patients with a primary diagnosis of a learning disability, (8)
patients with an exacerbated physical condition, which cannot
be safely managed in the MHICU, (9) pregnant women, who
would only be admitted to the MHICU in absolutely exceptional
circumstances.
All patients were assessed and diagnosed using DSM-IV-
TR criteria by trained psychiatrists. Individuals admitted to
the MHICU without a psychotic disorder diagnosis were
excluded. Patients who did not have CRP measured (n =
76; 27.1% of patients) were excluded. We also excluded
patients suffering from any physical illness that may have
influenced their immunological functioning (including non-
Hodgkins lymphoma, Hashimoto’s thyroiditis, HIV-AIDS and
recent septicaemia; n = 5), and patients with inflammatory
markers that were ≥ ± 2 standard deviations from the sample
mean (n= 11).
Patients with single admissions
Out of a total of 280 individuals screened for inclusion, 106
individuals were excluded based on the above criteria, leaving
a total of 174 individuals (117 males, 57 females) for entry into
analyses. Patients were between the ages of 15 and 76 years old.
Table 1 provides diagnostic frequencies of the acutely psychotic
sample.
Patients with multiple admissions
Thirty patients with 2 admissions (23 males, 7 females), between
19 and 57 years of age (M = 34.8, SD = 10.3) at first admission,
were included in the longitudinal analysis. Diagnoses included
bipolar disorder (n = 10), schizoaffective disorder (n = 11),
schizophrenia (n = 8), and psychosis NOS (n = 1). The mean
length of time between admissions was 295.9 days (SD = 261.2;
range= 13 to 898 days).
Blood Collection and Assays
Venous peripheral blood was collected within 1 week of
admission. Whole blood samples were shipped on ice to
the South-Eastern Area Laboratory Service where they were
processed using a chemiluminessence assay. Laboratory blood
tests routinely performed upon admission included: full blood
count, CRP and ANA. WBC and NLR were obtained from full
blood count results. Results of these blood tests were collected





Schizophrenia 60 60 34.48
Schizoaffective Disorder 45 105 25.86
Bipolar Disorder I and II 39 144 22.41
Psychotic Disorder NOS 13 157 7.47
Substance-Induced Psychotic Disorder 8 165 4.60
Brief Psychotic Disorder 2 167 1.15
Major Depressive Disorder (with psychotic
features)
2 169 1.15
Manic Episode 2 171 1.15
Schizophreniform Disorder 2 173 1.16




DSM-IV-TR, Diagnostic and Statistical Manual of Mental Disorders – Fourth Edition-TR;
†
Huntington’s Disease.
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from electronic medical records and entered into a separate
database for analysis. CRP results recorded as < 1 mg/L (n= 25)
were entered in the database at the minimum detection level (0.3
mg/L).
Clinical Data
Clinical data collected from patients included body mass index
(BMI), smoking status (smoker/non-smoker), illicit substance
use (drug-user/non-drug user; polysubstance abuse/non-
polysubstance abuse) and antipsychotic treatment upon
admission. See Table 2 for the frequency of patients receiving
different antipsychotics. The Health of the Nation Outcome
Scales (HoNOS), an indicator of health and social functioning,
was administered to the majority of patients (48).
Statistical Analyses
All data analyses were performed using SPSS version 23.
Antipsychotic dose was converted to mean daily chlorpromazine
(CPZ) equivalent dose based on standard guidelines (49). Effect
size calculations were measured as Cohen’s d (50).
For single admission analyses, a one-sample t-test was used
to compare the average levels of CRP with a clinical cut-
off of 3 mg/L (36). Participants were also grouped into two
categories; “normal CRP” with CRP < 3 mg/L and “elevated
CRP” with CRP ≥ 3 mg/L. Demographics, clinical variables and
other inflammatory markers were compared between elevated
and normal CRP groups using ANOVA or χ2-tests where
appropriate. ANCOVA was used to compare NLR and WBC
between CRP groups, covarying for age and BMI. For the
multiple admissions analyses, repeated measures ANCOVAs
(with age at initial admission as a covariate) were used to
determine significant differences in mean daily CPZ equivalent
dose, HoNOS, CRP, NLR, and WBC between initial and repeat
admissions.
Study Approval
This study was a retrospective analysis of patient’s records
blind to any personal identifying information. The study was
conducted under protocol 15/028 approved by the South-




Overall patient demographics, clinical, and inflammation
measures are shown in Table 3. The numbers of patients
classified by psychiatric diagnosis and the numbers of patients
receiving different antipsychotic combinations are provided in
Tables 1, 2. Mean CRP for the sample was 6.1 (SD = 6.7), which
was significantly higher than the clinical cut-off of 3, t(173) =
6.15, p < 0.01, d = 0.47. Mean NLR of 2.7 (SD = 1.1) was also
significantly elevated relative to the clinical cut-off for NLR of
2.2, t(170) = 5.88, p < 0.01, d = 0.45. Mean WBC was 7.8 (SD =
2.1), which was within the clinically normal range.
The majority of people with acute psychosis (n = 104, 59.8%)
had CRP levels ≥ 3 mg/L. Elevated NLR (≥ 2.2) was present in
70.2% (n = 73) of individuals with elevated CRP, but only 6.7%












































(n = 7) had elevated WBC (≥ 11). The majority of the people
with acute psychosis who were tested for signs of autoimmunity
had positive ANA titers (66.7%, i.e., 42/63 patients).
Subgroup Analyses Based on CRP Levels
As shown in Table 4, those with acute psychosis and elevated
CRP were significantly older and had a significantly greater BMI
than individuals who were acutely psychotic but had normal
CRP at the time of blood draw. There were no significant
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TABLE 3 | Demographics, clinical and inflammation measures in the acute
psychosis sample.
n Mean (SD) Normal range
Age (years) 174 38.7 (13.6)
Sex
Male/Female (%) 117/57 67.2%/32.8%
Ethnicity
Caucasian/Other 109/65 62.6%/37.4%
BMI 122 27.2 (6.4) 18.5–24.9
Smokers (%) 105 62.1%
Drug users (%) 91 52.3%
PSA (%) 56 32.2%
CPZ equivalent dose 169 1185.9 (1628.2)
HoNOS 134 15.5 (9.0)
CRP 174 6.1 (6.7) <3.0
NLR 170 2.7 (1.1) <2.2
WBC 166 7.8 (2.1) 3.5–11
ANA positive (%) 42 66.7%
PSA, polysubstance abuse; CPZ, mean daily chlorpromazine; HoNOS, Health of the
Nation Outcome Scale; BMI, body mass index; CRP, C-reactive protein; NLR, neutrophil-
to-lymphocyte ratio; WBC, white blood cell count. Unless otherwise specified, values refer
to means and s.d. in parentheses.
differences between the CRP subgroups (≥3 mg/L vs. < 3 mg/L)
in relation to antipsychotic dosage, smoking status, drug use
status, polysubstance abuse (PSA), HoNOS scores, or percent
ANA positive. After co-varying for age and BMI, NLR remained
significantly higher in patients with elevated CRP compared to
patients with normal CRP. There was a trend toward a significant
increase inWBC in the elevated CRP group relative to the normal
CRP group after covarying for age and BMI.
As shown in Table 5, CRP levels were significantly reduced at
repeat admission compared to initial admission. However, mean
CRP was significantly elevated relative to the clinical cut-off at
both initial admission (M = 12.1, SD = 12.0), t(29) = 4.18, p <
0.001, and repeat admission (M = 7.8, SD = 8.0), t(29) = 3.29, p
= 0.003. There were no significant differences in NLR and WBC
between admissions. NLR was significantly elevated relative to
the clinical cut-off at initial admission (M = 2.9, SD = 1.6), t(27)
= 2.35, p = 0.03, and repeat admission (M = 2.9, SD = 1.2),
t(27) = 3.02, p = 0.005. Mean WBC was within normal levels at
both admissions. There were no significant differences in relation
to mean daily CPZ equivalent dose and HONOS scores between
admissions.
Discussion
This study found CRP levels to be significantly elevated in
patients with acute psychosis compared to clinical cut-offs,
supporting previous work (45, 51). A large proportion (∼60%)
of the current sample had a CRP above the normal clinical range.
NLR, which is the ratio of the number of most abundant white
blood cells (neutrophils) to the total number of lymphocytes
(which includes T cells, B cells. monocytes and Natural Killer
Cells), was also significantly elevated in this acutely psychotic
sample, confirming previous reports of increased NLR in
schizophrenia (23, 24). WBC was within normal levels; however,
there was a trend toward WBC being higher in the elevated
CRP group compared to the normal CRP group, which is
consistent with findings from a recent study that reported a
positive relationship between leukocytes and CRP in 213 patients
with schizophrenia (52). Furthermore, a large proportion of
patients (∼67%) in the current sample had positive ANA, which
is a much higher frequency than previously reported (∼20%)
in chronically ill patients with schizophrenia (22) and higher
than reported for healthy individuals (∼26%) (53). Since known
autoimmune disorders was an exclusion for being included
in our analyses, elevated inflammatory markers would most
likely not be attributed to other physical disorders in this
instance.
We also found that there was a significant decrease in
CRP levels at repeat admission compared to initial admission;
however, CRP at both admissions was significantly elevated
compared to the clinical cut-off. There was no significant
change in NLR or WBC across both admissions. These findings
demonstrate that CRP and NLR (but not WBC) are consistently
elevated above normal levels during acute psychotic episodes.
This may indicate that a subset of acutely psychotic individuals
with elevated CRP or NLR may benefit most from adjunctive
anti-inflammatory treatments initially at admission or later,
possibly to prevent further admissions.
However, there are some potential confounding factors that
make the connection between inflammation and psychotic
illnesses uncertain. There was a significant difference between
normal and elevated CRP groups in relation to age and BMI,
which is consistent with previous findings that higher CRP
level is associated with older age and greater BMI (25, 54).
However, after co-varying for age and BMI, NLR remained
significantly greater in patients with elevated relative to patients
with normal CRP levels suggesting that CRP is a marker
of brain illness/dysfunction in these cases and not simply a
reflection of aging or excess weight. There was no significant
difference between elevated and normal CRP groups in relation
to antipsychotic dosage, supporting meta-analytical findings that
CRP is not strongly modulated by antipsychotic dose (25).
In contrast to previous studies that have shown smoking and
drug use to be related to elevated CRP (55, 56), we found no
significant difference between the patients with acute psychosis
who displayed elevated and normal CRP in the proportion
of smokers, drug users or poly substance abusers. Thus, the
potential confounds did not appear to drive our findings in
relation to the effects of CRP in this sample of acutely ill psychosis
patients.
Other limitations include the lack of symptom severity
measures, cognitive assessments and a restricted number of
inflammation markers assessed. However, a common difficulty
faced when working with acutely psychotic individuals admitted
to inpatient hospitals is that these patients are frequently too
unwell to complete standardized assessments. These patients met
the clinical criteria for admission to the Mental Health Intensive
Care Unit at intake, which is indicative of severe symptomatology
and dysfunction.
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TABLE 4 | Characteristics of the acute psychosis sample in the normal (CRP < 3 mg/L) and elevated (CRP ≥ 3 mg/L) CRP groups.
n “Normal”
CRP < 3 mg/L
n “Elevated”




Age 70 35.4 (12.8) 104 40.9 (13.6) F = 7.26 0.008* 0.42
BMI 54 24.8 (5.4) 68 29.1 (6.6) F = 15.00 <0.001* 0.71
Smokers (%) 45 42.9% 60 57.1% χ2 = 0.79 0.37 -
Drug users (%) 38 41.8% 53 58.2% χ2 = 0.19 0.67 -
PSA (%) 25 44.6% 31 55.4% χ2 = 0.67 0.51 -
CPZ equivalent 68 1067.9 (1589.6) 101 1265.4 (1656.8) F = 0.60 0.44 0.12
HoNOS 56 15.3 (10.0) 78 15.6 (8.2) F = 0.04 0.84 0.04
NLRa 53 2.4 (1.0) 66 2.9 (1.1) F = 7.75 0.006* 0.48
WBCa 53 7.3 (2.0) 63 8.1 (1.9) F = 3.22 0.08 0.41
ANA positive (%) 18 42.9% 24 57.1% χ2 = 0.13 0.72 -
CRP, C-reactive protein; BMI, body mass index; CPZ, chlorpromazine; PSA, polysubstance abuse; HoNOS, Health of the Nation Outcome Scale; NLR, neutrophil-to-lymphocyte ratio;
WBC, white blood cell count; ANA, anti-nuclear antibodies. Unless otherwise specified, values refer to means and s.d. in parentheses. aANCOVA results covaring for age and BMI.
*p < 0.01.
TABLE 5 | Difference in inflammatory markers at initial and repeat admission with acute psychosis.
n Initial admission 2nd admission Mean difference (SD) F p Cohen’s d
CPZ equivalent 28 1700.2 (1877.8) 1797.9 (2095.4) −97.7 (2135.1) 0.95 0.34 0.05
HONOS 18 14.7 (6.4) 12.7 (6.3) −2.0 (6.8) 0.01 0.93 0.31
CRP 30 12.1 (12.0) 7.8 (8.0) 4.3 (16.3) 4.67 0.04* 0.42
NLR 28 2.9 (1.6) 2.9 (1.2) 0.1 (1.4) 2.89 0.10 0.00
WBC 27 8.3 (2.4) 8.8 (2.8) −0.5 (3.6) 0.35 0.56 0.19
Repeated measures ANCOVA covarying for age at initial admission. CRP, C-reactive protein; NLR, neutrophil-to-lymphocyte ratio; WBC, white blood cell count. Unless otherwise
specified, values refer to means and s.d. in parentheses. *p < 0.05.
In sum, after covarying for age and BMI, elevated CRP, and
NLR appear to be characteristic of a substantial subset of people
with acute psychosis. The findings from Study 1 support the
hypothesis that a large subset (∼60%) of individuals with acute
psychosis display elevated markers of inflammation which is
sustained across admissions for acute psychosis. Next, in Study 2
(below) we tested the relationship of CRP to symptoms, cognition
and brain cortical thickness in a chronically ill sample of people
with schizophrenia.





The second study is derived from baseline data collected in
our previously published clinical trial of a hormonal based
treatment for schizophrenia (57). The current work represents
our first assessment of CRP as an assay of immune system
function in schizophrenia and the degree to which cognitive,
symptom, daily function, and brain volume variables differ
in relation to CRP in this sample. Only participants who
provided a sufficient quantity of blood for analysis of CRP were
included.
Chronically ill patients with schizophrenia
Eighty-five adult outpatients (51 males, 34 females) with
schizophrenia or schizoaffective disorder, between 20 and 51
years of age, were included. All participants had been receiving
antipsychotics for at least 1 year before entering the study (see
Table 6 for the numbers of people receiving each antipsychotic or
combination of antipsychotics). A diagnosis of schizophrenia (n
= 54) or schizoaffective disorder (n = 31) was determined using
the Structured Clinical Interview for Diagnostic and Statistical
Manual IV-TR Axis I Disorders (SCID) (58) by a clinician trained
in administration of the SCID and was confirmed independently
by another clinician. Patients with a concurrent Axis I psychiatric
diagnosis, a history of substance abuse or dependence (within
the past 5 years), head injuries with loss of consciousness,
seizures, central nervous system infection, untreated diabetes,
or hypertension, or mental retardation were excluded. Women
were excluded if they were pregnant. Seventy-four patients had
their height and weight collected for BMI calculation. Sixty-nine
patients also provided information about whether they were a
smoker or non-smoker.
Healthy comparison group
Seventy-one healthy adults (34 males, 37 females) between 20
and 50 years of age were included. Exclusion criteria included a
personal history of or a first-degree relative with a DSM-IV Axis
I psychiatric diagnosis, history of substance abuse or dependence
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(within the past 5 years), head injuries with loss of consciousness,
seizures, central nervous system infection, mental retardation, or
untreated diabetes or hypertension.
Assessments
Cognitive assessments
All participants were administered a four subtest version of the
Wechsler Adult Intelligence Scale – Third Edition (WAIS-III)
(59) (consisting of Arithmetic, Similarities, Picture Completion
and Digit Symbol subtests) as an estimate of current IQ, and the
Wechsler Test of Adult Reading (WTAR) (60) as an estimate
of premorbid IQ in schizophrenia. Working memory, verbal
concept formation, visual perceptual organization, verbal
fluency, attention/perceptual-motor processing speed and
immediate and delayed verbal memory were assessed using
WAIS-III Letter Number Sequencing (LNS) and Arithmetic,
WAIS-III Similarities, WAIS-III Picture Completion, the
Controlled Oral Word Association Test (COWAT) letter fluency
(61), Form A of the Trail Making Test (TMT-A) (62) and Logical
Memory I and II (LMI and LMII) of the Wechsler Memory
Scale—Revised (63), respectively. TMT-A was incorporated into
the battery after initiation of the study, which resulted in a lower
total number of patients (n= 64) completing this measure.
Symptom and functional assessments
Symptom severity was assessed in patients using the Positive
andNegative Syndrome Scale (PANSS) (64). Inter-rater reliability
for the PANSS was high with an average intra-class correlation
coefficient of 0.90. Negative emotional states, daily function
and quality of life were assessed with the 21-item version of
the Depression, Anxiety and Stress Scale (DASS-21) (65), the
Short Form 36 Version 2 Health Survey Questionnaire (SF-36v2)
(66), and the Schizophrenia Quality of Life Scale (SQLS) (67),
respectively.
Blood collection and processing
Peripheral venous blood was collected from all participants in
8ml Serum-separating tubes (SST Vacutainer, Becton Dickinson,
Franklin Lakes, NJ) and 9ml ethylenediaminetetraacetic
acid (EDTA) tubes (Vacuette Vacutainer, Greiner Bio-One,
Kremsmünster, Austria). Plasma was collected from EDTA
tubes via centrifugation for 15min at 2000 x g. SST tubes were
incubated at room temperature for 30min to allow for the
blood to clot. Upon clotting, the serum was then collected via
centrifugation for 5min at 2000 x g. Plasma and serum were then
aliquoted into protein low-binding tubes (Eppendorf, Hamburg,
Germany) and stored at−80◦C until the day of the assay.
CRP was measured in plasma using a high-sensitivity
Enzyme-linked immunosorbent assay (ELISA) according to
the manufacturer’s instructions (IBL-international, Hamburg,
Germany). Ten microliters of plasma was diluted serially up
to 1:1,000 and each assay was run back to back with samples
in duplicate by the same investigator, who was blind to the
diagnosis. A five-point standard curve was generated using 10,
5, 1, 0.4, and 0µg/ml calibrators that were prepared by the
manufacturer. The average coefficient variance across all plates
was 3.23%. The sample reads ranged from 0.06 mg/L to 23.92
mg/L. A minimum detectable value replacement of 0.003 was
used for 13 data points that were below the respective minimal
detectable value on all protein analytes.
MRI data collection and processing
From the total number of participants, 32 patients and
19 controls did not receive an MRI scan for reasons
including electing not to receive an MRI scan, not able
to physically fit in the MRI scanner, and/or experiencing
claustrophobia. Thus, a subsample of participants (44 patients,
51 healthy controls) received a structural MRI scan of the
brain. The MRI scans were performed using a 3-Tesla
Phillips Achieva scanner with an 8-channel head coil located
at Neuroscience Research Australia (Randwick, NSW). T1
weighted high-resolution anatomical scans were obtained (1mm
slice thickness, no gap, 180 slices, TR = 5.4ms, TE =
2.4ms, field of view 256mm). After visual inspection of
scans for motion and other artifacts and neuroanatomical
abnormalities, data from 41 patients and 51 controls were
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TABLE 7 | Demographics, cognitive, symptom severity, negative emotional states, daily function measures, and C-reactive protein levels in chronically ill patients with
schizophrenia and healthy controls.






Age (years) 85 35.8 (8.6) 71 32.2 (8.3) t = 2.68 <0.01* 0.43
Sex (number) 85 71
Male/Female 51/34 34/37 χ2 = 2.29 0.13 -
Ethnicity (number) 85 71
Caucasian/Other 74/11 59/12 χ2 =0.83 0.51 -
Education (years) 85 12.5 (2.3) 71 14.7 (2.3) t = 5.72 < 0.01* 0.96
Age of illness onset (years) 85 22.8 (5.8) – – – – –
Illness duration (years) 85 13.0 (7.5) – – – – –
CPZ equivalent (mg) 85 563.2 (484.2) – – – – –
IMMUNE FUNCTIONING
CRP 76 3.4 (3.2) 70 1.8 (2.7) t = 3.29 0.01* 0.55
COGNITIVE TESTS
WTAR 85 101.9 (9.2) 71 107.7 (9.0) t = 3.96 < 0.01* 0.64
WAIS-III IQ 85 91.1 (12.8) 71 107.3 (15.4) t = 7.20 < 0.01* 1.15
WAIS-III Similarities 85 9.3 (2.9) 71 10.8 (2.7) t = 3.38 < 0.01* 0.54
WAIS-III Arithmetic 85 7.9 (3.2) 71 10.9 (3.2) t = 5.67 < 0.01* 0.94
WAIS-III Digit Symbol 85 7.0 (2.4) 71 11.5 (3.4) t = 9.49 < 0.01* 1.53
WAIS-III Picture Completion 85 8.6 (2.4) 71 10.8 (2.8) t = 5.22 < 0.01* 0.84
WAIS-III LNS 85 8.1 (2.7) 71 11.1 (2.8) t = 6.82 < 0.01* 1.09
WMS-R LMI 85 7.9 (3.5) 71 11.9 (3.3) t = 7.24 < 0.01* 1.18
WMS-R LMII 85 6.1 (3.3) 71 10.4 (3.5) t = 7.71 < 0.01* 1.26
TMT-A 64 39.0 (13.2) 56 25.9 (8.9) t = −6.46 < 0.01* 1.16
COWAT verbal fluency 85 37.3 (11.0) 71 41.6 (11.4) t = 2.40 0.02* 0.38
SYMPTOM AND DAILY FUNCTION
PANSS
Positive 85 15.2 (4.5) – – – – –
Negative 85 14.1 (5.9) – – – – –
General 85 30.3 (8.5) – – – – –
Total 85 59.5 (15.9) – – – – –
DASS
Depression 85 12.6 (10.0) 66 3.2 (5.1) t = 7.52 < 0.01* 1.18
Anxiety 85 10.5 (8.0) 66 2.6 (3.9) t = 7.95 < 0.01* 1.26
Stress 85 14.9 (9.9) 66 6.4 (7.1) t = 6.16 < 0.01* 0.99
SF-36v2 total 85 113.2 (23.8) 66 141.4 (10.1) t = 9.78 < 0.01* 1.54
SQLS total 85 47.6 (18.5) 66 22.4 (10.3) t = 10.44 < 0.01* 1.68
CPZ, chlorpromazine; WTAR, Wechsler Test of Adult Reading; WAIS-III, Wechsler Adult Intelligence Scale 3rd Edition; WMS-R LMI, Wechsler Memory Scale Revised Logical Memory I;
WMS-R LMII, Wechsler Memory Scale - Revised Logical Memory II; LNS, Letter Number Sequencing; TMT-A, Trail Making Test Form A; COWAT, Controlled Oral Word Association Test;
PANSS, Positive and Negative Syndrome Scale; DASS, Depression Anxiety and Stress Scale; SF-36v2, Short Form 36 Version 2 Health Survey Questionnaire; SQLS, Schizophrenia
Quality of Life Scale; CRP, C-reactive protein. Unless otherwise specified, values refer to means and s.d. in parentheses. *p < 0.05.
analyzed for cortical thickness. The scans were processed
using Mac OSX 10.8 running FreeSurfer software (version
5.1.0, Athinoula A. Martinos Center for Biomedical Imaging,
Massachusetts, USA). A detailed methodological description of
the FreeSurfer cortical reconstruction, volumetric segmentation
and subsequent deformable procedures (including published
references) is available at http://surfer.nmr.mgh.harvard.edu/.
Processed scans were visually evaluated and manually edited as
necessary by trained personnel. Cortical thickness data for each
region were obtained based on the FreeSurfer Desikan-Killiany
atlas.
Statistical Analyses
Data analysis was performed using SPSS version 23. Where
possible, age- and sex-adjusted scaled scores were used for the
cognitive tests. Extreme outliers (≥± 2 standard deviations from
the mean) for the CRP variable were excluded from the analysis
(total excluded n = 10, schizophrenia group n = 9, healthy
control group n= 1).
Demographic, clinical, cognitive, symptom severity, negative
emotional states, quality of life, and daily function scores were
compared between the chronically ill schizophrenia group and
healthy control group using t-tests or χ2 as appropriate.
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Based on clinical cut-off scores, all participants were grouped
into two categories: “normal CRP” with CRP < 3 mg/L and
“elevated CRP” with CRP≥ 3mg/L (36).χ2 tests were performed
to determine if there were significant differences in the numbers
of participants among the CRP groups in patients and controls.
An ANOVA was performed between the acute psychosis patient
group (from Study 1) and the chronically ill schizophrenia patient
group (from Study 2) to determine the extent to which CRP levels
differed between these patient groups. Demographic, clinical,
cognitive, symptom severity, negative emotional states, quality of
life, and daily function scores were compared among normal CRP
groups in healthy controls and normal and elevated CRP groups
in schizophrenia patients using univariate ANOVAs with False
Discovery Rate (FDR) corrections for multiple comparisons (68).
Effect size calculations were reported as Cohen’s d (50).
Further analyses included paired t-tests in a subset of 46
patients with schizophrenia who had elevated CRP (n = 23) and
normal CRP (n= 23) who were matched within 2 points on BMI
to compare performance on any measures that were significantly
different between the elevated and normal CRP groups (i.e.,
WAIS-III IQ and Arithmetic) to control for BMI.
FreeSurfer cortical thickness estimates for the left and right
hemispheres were summed to create a composite measure for
each brain region. Simple linear regression models (backward
elimination) were used to model potential predictors of cortical
thickness. Predictor variables consisted of CRP, diagnostic group,
age at sampling and sex. The criterion for backward elimination
was F ≥ 0.1.
Study Approval
All participants provided written informed consent consistent
with the Declaration of Helsinki which was obtained after the
nature and possible consequences of the study were explained.
The study was conducted under protocols approved by the
University of New South Wales (07/121 and 09/187), South
Eastern Sydney Local Health District (07-259) Human Research
Ethics Committees and the Queen Elizabeth Hospital Ethics and
Human Research Committee, Adelaide (2010188).
Results
Sample Characteristics
The number of chronically ill patients with schizophrenia
receiving different antipsychotics are provided inTable 6. Cohort
demographics, cognitive, symptom, negative emotional states,
and daily functioning scores, and CRP levels are provided in
Table 7. Relative to healthy controls, patients with schizophrenia
were significantly older (although the groups were only 9.4%
different in age) and had significantly less education. Patients
with schizophrenia also had significantly lower (worse) scores
for cognitive, negative emotions, and daily functioning relative
to controls. As predicted, the patients with schizophrenia had
significantly elevated CRP levels relative to controls (an 88.9%
increase, see Table 7). There were no significant differences
between schizophrenia and control groups in relation to sex
or ethnicity ratios. The patients displayed mild to moderate
symptom severity based on Positive and Negative Syndrome
Scale (PANSS) scores, were chronically ill with a typical mean
FIGURE 1 | C-Reactive Protein (CRP) levels (in mg/L) in patients admitted for
an acute psychotic episode, chronically ill patients with schizophrenia, and
healthy controls (means provided with standard error), *p < 0.01, **p < 0.001.
age of onset and the majority of patients were receiving second
generation antipsychotic medication (see Table 6).
CRP Levels
There was a significant difference in the proportions of people
with elevated CRP in schizophrenia and healthy control groups;
χ2
(1)
= 9.16, p < 0.01. Forty three percent of people with
schizophrenia had CRP ≥ 3 mg/L (n = 33; CRP range 3.0–12.3)
compared to 20% of healthy controls with CRP ≥ 3 mg/L (n =
14; CRP range 3.0–13.5).
There was also a significantly higher CRP level in the acute
psychosis patient group from Study 1 (M = 6.1, SD = 6.7)
relative to the chronically ill patient group from Study 2 [M
= 3.4, SD = 3.2, F(1,248) = 11.36, p = 0.001, see Figure 1], as
well as a significant difference in the proportions of people in
the elevated versus normal CRP groups among acute psychosis




Subgrouping Based on CRP Levels
As shown in Table 8, there were no significant differences
between elevated and normal CRP groups in healthy controls
in relation to any of the demographic, negative emotional
states, daily function, quality of life, or cognitive measures after
adjustment for multiple comparisons. Table 9 shows that after
adjustment for multiple comparisons, there were significant
differences between the elevated and normal CRP groups in
patients with schizophrenia in relation to sex, BMI, current IQ
(WAIS-III IQ) and working memory (i.e., WAIS-III Arithmetic
subtest), with a large effect size for working memory such
that performance was significantly poorer in the elevated CRP
group of patients. Paired t-tests revealed a significant difference
in working memory (WAIS-III Arithmetic) remained between
the patients with schizophrenia displaying normal and elevated
CRP who were matched on BMI (see Table 10). There was no
significant difference between the matched groups on current IQ
(WAIS-III IQ).
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F or χ2 p FDR-adjusted p Cohen’s d
CLINICAL VARIABLES
Age (years) 56 32.3 (8.2) 14 32.1 (9.1) F = 0.00 0.96 0.96 0.02
Sex (number)
Male/Female 27/29 6/8 χ2 = 0.13 0.72 0.96 -
Ethnicity (number) χ2 = 1.23 0.27 0.96 -
Caucasian/Other 45/11 13/1
Education (years) 56 14.7 (2.1) 14 14.4 (3.0) F = 0.20 0.66 0.96 0.12
READING AND CURRENT IQ
WTAR 56 109.3 (8.3) 14 103.1 (8.8) F = 6.13 0.02 0.13 0.76
WAIS-III IQ 56 109.3 (13.8) 14 100.8 (20.0) F = 3.53 0.07 0.13 0.49
COGNITIVE TESTS
WAIS-III Similarities 56 11.2 (2.7) 14 9.6 (2.3) F = 4.21 0.04 0.13 0.64
WAIS-III Arithmetic 56 11.1 (3.0) 14 10.1 (3.6) F = 1.08 0.30 0.36 0.30
WAIS-III Digit Symbol 56 11.8 (3.2) 14 10.0 (3.6) F = 3.47 0.07 0.13 0.53
WAIS-III Picture Completion 56 11.1 (2.6) 14 9.5 (3.5) F = 3.71 0.06 0.13 0.52
WAIS-III LNS 56 11.2 (3.0) 14 10.4 (1.9) F = 0.98 0.33 0.36 0.32
WMS-R LMI 56 12.3 (3.3) 14 10.7 (3.2) F = 2.62 0.11 0.17 0.49
WMS-R LMII 56 10.9 (3.5) 14 8.6 (2.9) F = 5.22 0.03 0.13 0.72
TMT-A 42 24.8 (9.2) 13 28.4 (6.7) F = 1.74 0.19 0.26 0.45
COWAT verbal fluency 56 42.4 (11.4) 14 39.4 (10.7) F = 0.83 0.37 0.37 0.27
NEGATIVE EMOTION AND DAILY FUNCTION
DASS
Depression 51 3.0 (5.1) 14 4.1 (5.5) F = 0.55 0.46 0.63 0.21
Anxiety 51 2.5 (3.8) 14 4.1 (5.5) F = 0.47 0.50 0.63 0.34
Stress 51 6.1 (7.2) 14 8.0 (6.9) F = 0.80 0.38 0.63 0.27
SF-36 v2 Total 51 142.4 (8.1) 14 136.6 (14.4) F = 3.92 0.05 0.25 0.50
SQLS Total 51 22.4 (10.5) 14 23.4 (10.0) F = 0.10 0.75 0.75 0.10
WTAR, Wechsler Test of Adult Reading; WAIS-III, Wechsler Adult Intelligence Scale 3rd Edition; LNS, Letter Number Sequencing; WMS-R LMI, Wechsler Memory Scale Revised Logical
Memory I; WMS-R LMII, Wechsler Memory Scale - Revised Logical Memory II; TMT-A, Trail Making Test Form A; COWAT, Controlled Oral Word Association Test; DASS, Depression
Anxiety and Stress Scale; SF-36v2, Short Form 36 Version 2 Health Survey Questionnaire; SQLS, Schizophrenia Quality of Life Scale.
Cortical Thickness Analysis
Results from the regression analysis using diagnostic group,
age, sex, and CRP revealed significant contributions of
the independent variables to the prediction of cortical
thickness in several frontal and temporal regions in
addition to the insula and paracentral gyrus (see Table 11
and Figure 2). In relation to our main variable of interest,
CRP significantly predicted cortical thickness in most (8/9)
regions, with CRP predicting from 3.9% of the variance
in the frontal pole and middle temporal lobe to 7.7%
of the variance in the temporal pole. The relationships
between CRP levels and cortical thickness were inverse,
demonstrating that as CRP levels increased, cortical thickness
decreased.
As would be expected, age was generally the strongest
predictor of cortical thickness in most regions showing
significant results, predicting from 6.1% of the variance in the
temporal pole to 18.8% of the variance in the medial orbital
frontal cortex. Also, as expected, diagnostic group predicted from
4.3% of cortical thickness in the lateral orbital frontal cortex
to 6.3% of cortical thickness in superior frontal gyrus, middle
temporal lobe, and entorhinal cortex.
Discussion
In relation to elevated CRP, there was a significant difference
between the proportions of chronically ill patients with
schizophrenia (43%) and healthy controls (20%) who could be
classified as having elevated levels of inflammation. These
findings suggest the existence of a low-grade systemic
inflammation in nearly half of the patients studied. This is
consistent with our report of a similar proportion (∼40%) of
chronically ill patients displaying elevated cytokine mRNA
expression in post-mortem prefrontal cortex tissue (17) and
displaying elevated cytokine mRNA expression in blood (69).
On average, the chronically ill patients with schizophrenia
displayed significantly lower CRP levels than the acute psychosis
group, supporting previous work showing that CRP may
decrease following antipsychotic treatment and resolution of
acute psychotic episodes (42). Thus, a substantial proportion
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TABLE 9 | Comparison of demographic, clinical, cognitive, symptom severity, negative emotional states, daily function and quality of life measures between normal and
elevated CRP groups in patients with schizophrenia.
n “Normal” CRP <3 mg/L n “Elevated” CRP ≥3 mg/L F or χ2 p FDR-adjusted p Cohen’s d
CLINICAL VARIABLES
Age (years) 43 36.3 (8.8) 33 34.9 (8.0) F = 0.49 0.49 0.69 0.17
Sex (number)
Male/Female 32/11 14/19 χ2 = 8.00 0.005 0.03* -
Ethnicity (number)
Caucasian/Other 35/8 30/3 χ2 = 1.37 0.24 0.60 -
Education (years) 43 13.0 (2.4) 33 12.3 (2.3) F = 1.73 0.19 0.60 0.30
Smokers (number) 18 14 χ2 = 0.82 0.84 0.84 -
CPZ equivalent 43 486.9 (435.6) 33 562.7 (461.8) F = 0.54 0.47 0.69 0.17
Illness duration 43 12.7 (8.0) 33 13.4 (7.2) F = 0.16 0.69 0.77 0.09
Age of onset 43 23.3 (6.1) 33 22.1 (5.1) F = 0.89 0.35 0.69 0.22
BMI 38 29.3 (6.2) 28 33.7 (6.0) F = 8.22 0.006 0.03* 0.72
IMMUNE FUNCTIONING
NLR 42 2.4 (1.2) 31 2.5 (1.0) F = 0.36 0.55 0.69 0.09
PREMORBID AND CURRENT IQ
WTAR 43 102.7 (10.4) 33 102.2 (8.0) F = 0.40 0.84 0.84 0.05
WAIS-III IQ 43 95.1 (12.5) 33 87.2 (11.7) F = 7.87 0.006 0.03* 0.65
COGNITIVE TESTS
WAIS-III Similarities 43 9.8 (2.8) 33 9.0 (3.1) F = 1.22 0.27 0.41 0.25
WAIS-III Arithmetic 43 9.1 (3.1) 33 6.6 (3.0) F = 11.57 0.001 0.01* 0.79
WAIS-III Digit Symbol 43 7.7 (2.4) 33 6.4 (2.2) F = 5.97 0.02 0.07 0.57
WAIS-III Picture Completion 43 8.8 (2.4) 33 8.3 (2.2) F = 1.04 0.31 0.41 0.22
WAIS-III LNS 43 8.5 (2.7) 33 7.5 (2.8) F = 2.74 0.10 0.28 0.38
WMS-R LMI 43 8.1 (3.4) 33 7.4 (3.4) F = 0.98 0.32 0.41 0.24
WMS-R LMII 43 6.3 (3.2) 33 5.6 (3.1) F = 0.91 0.34 0.41 0.22
TMT-A 33 38.0 (12.1) 28 41.1 (12.6) F = 0.83 0.37 0.41 0.25
COWAT verbal fluency 43 39.2 (11.1) 33 36.3 (11.1) F = 1.28 0.26 0.41 0.26
SYMPTOMS/DAILY FUNCTION
PANSS
Positive 43 14.7 (4.1) 33 15.6 (4.7) F = 0.72 0.40 0.72 0.20
Negative 43 13.9 (5.7) 33 14.6 (6.6) F = 0.26 0.62 0.77 0.16
General 43 29.7 (8.6) 33 31.5 (8.5) F = 0.79 0.38 0.72 0.21
Total 43 58.3 (15.4) 33 61.6 (16.7) F = 0.81 0.37 0.72 0.21
DASS
Depression 43 13.5 (9.5) 33 12.1 (10.7) F = 0.40 0.53 0.77 0.15
Anxiety 43 10.1 (7.7) 33 12.1 (8.2) F = 1.22 0.27 0.72 0.26
Stress 43 15.4 (9.6) 33 15.2 (9.9) F = 0.01 0.95 0.95 0.01
SF-36 v2 Total 43 115.9 (18.7) 33 107.9 (29.1) F = 2.07 0.16 0.72 0.33
SQLS Total 43 48.7 (16.6) 33 47.0 (19.3) F = 0.17 0.68 0.77 0.10
CPZ, chlorpromazine; BMI, body mass index; NLR, neutrophil-to-lymphocyte ratio; WTAR, Wechsler Test of Adult Reading; WAIS-III, Wechsler Adult Intelligence Scale 3rd Edition; LNS,
Letter Number Sequencing; WMS-R LMI, Wechsler Memory Scale Revised Logical Memory I; WMS-R LMII, Wechsler Memory Scale - Revised Logical Memory II; TMT-A, Trail Making
Test Form A; COWAT, Controlled Oral Word Association Test; PANSS, Positive and Negative Syndrome Scale; DASS, Depression Anxiety and Stress Scale; SF-36v2, Short Form 36
Version 2 Health Survey Questionnaire; SQLS, Schizophrenia Quality of Life Scale. *p < 0.05.
of chronically ill patients with schizophrenia display elevated
peripheral inflammation markers and CRP in particular.
Some studies have shown that elevated CRP is associated
with poorer cognitive performance (verbal memory, global
cognition) both in patients with schizophrenia (40) and healthy
older adults (70). In the current study, the elevated CRP
schizophrenia group displayed significantly worse performance
on a measure of working memory compared to the normal
CRP schizophrenia group after matching for BMI. These results
suggest that immune-related mechanisms may be a contributing
factor to working memory/reasoning deficits (which are known
to be particularly dependent on a healthy prefrontal cortex)
in schizophrenia. Given that working memory deficits are
particularly predictive of long-term functional outcome (71),
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TABLE 10 | Comparison of current IQ and working memory measures between






BMI 23 32.2 (5.8) 23 32.3 (5.8) 22 −0.55 0.59
WAIS-III IQ 23 95.8 (11.6) 23 89.4 (11.3) 22 1.64 0.12
Arithmetic 23 9.2 (2.8) 23 7.0 (3.0) 22 2.69 0.01*
WAIS-III IQ, Wechsler Adult Intelligence Scale, 3rd Edition. *p = 0.01.
the influence of elevated CRP on working memory/reasoning
suggests that adjunctive anti-inflammatory treatments may
reduce cognitive deficits and improve daily function in a
substantial subset of patients with schizophrenia. Our results
suggest that measuring CRP levels in blood of chronically ill
people with schizophrenia would also be an indicator of impaired
prefrontal cortex function.
Contrary to our hypotheses, there were no significant
differences between elevated and normal CRP patient groups in
relation to symptom severity as measured by PANSS ratings. This
finding is discordant with results from a previous study which
reported greater severity of negative and general symptoms
in patients with schizophrenia displaying elevated CRP levels
(42). However, this difference may be due to inclusion/exclusion
criteria and sampling differences. For instance, the sample used
in the previous study consisted of patients with moderately high
levels of symptom severity (42), whereas, the patients in the
current sample displayed mild to moderate levels of symptom
severity. In support of this view, the results of the current
study are consistent with other studies that have failed to find
an association between inflammation markers and symptom
severity in patients with mild to moderate symptom severity
(40). Thus, the presence of greater illness severity appears to be
necessary to reveal the relationship between illness severity and
inflammation.
Our study is the first to assess brain cortical thickness
measures in relation to CRP levels in patients with schizophrenia
and healthy controls. CRP levels made a significant contribution
to cortical thickness in 8 out of 9 regions including the
frontal pole, medial orbital frontal, lateral orbital frontal, middle
temporal cortices, temporal pole, entorhinal cortex, insula, and
paracentral gyrus in both patients and controls. An inverse
relationship between CRP levels and cortical thickness in
prefrontal regions is consistent with the elevated CRP patients
with schizophrenia displaying a significantly worse working
memory performance relative to patients with schizophrenia
who display normal CRP levels; however, it is typically
aberrant activity in the dorsolateral prefrontal cortex, not
other prefrontal regions that is associated with changes in
working memory in people with schizophrenia (72). However,
others have shown activation of the inferior frontal gyrus
in healthy adults and decreased blood flow to the middle
temporal gyrus in coronary artery disease during mental stress
induced by arithmetic (73) suggesting involvement of both
ventral regions and temporal regions to math challenges. Since
thinner cortex in temporal regions also showed a relationship
to elevated CRP, CRP might have been expected to correlate
with episodic memory performance. Although there was such
a relationship (see Table 8 for delayed recall in controls) it
did not survive correction for multiple comparisons suggesting
that this relationship between CRP and delayed memory was
less robust than that for working memory and prefrontal
cortex. One limitation of this study would be in relation to
the restricted number of inflammation markers assessed in our
study; however, we have reported on the relationship of other
peripheral inflammation markers (e.g., IL-1β) to cognition and
brain volume in a smaller sample of chronically ill patients
with schizophrenia (30). Overall, these results in relation to
CRP levels and cortical thickness provide further support
for the role of inflammatory processes especially influencing
prefrontal brain structure and cognition in patients with
schizophrenia.
GENERAL DISCUSSION
We assessed the proportions of patients displaying a marker of
inflammation (CRP) in two independent samples (in chronically
ill patients with schizophrenia and over repeated admissions
in patients experiencing an acute psychotic episode) and the
ability of CRP to predict cortical thickness. The results of our
study in patients admitted for an acute psychotic episode showed
that acute psychosis is often associated with a relatively high
level of systemic inflammation as measured by elevated CRP,
NLR and positive ANA titers. In our study of chronically ill
patients with schizophrenia, we showed that CRP was also
significantly elevated relative to healthy controls. A larger
proportion of individuals (∼60%) with acute psychosis had
elevated levels of CRP, compared to ∼44% of the chronically
ill patients with schizophrenia. This is consistent with findings
that elevated CRP may decrease with resolution of psychotic
symptoms (45). Some healthy controls also displayed elevated
CRP, although the proportion (20%) was significantly lower
than the proportions displaying elevated CRP in chronically ill
patients with schizophrenia and those patients admitted for an
acute psychotic episode. The finding of elevated CRP in some
healthy controls is not unexpected as slightly increased and/or
chronic immune activation can be found in otherwise healthy
samples given that common inflammatory processes, including
allergies, asthma, or arthritis may be present in otherwise healthy
individuals, e.g., the prevalence of arthritis is 22.7% annually in
the US (74).
The chronically ill patients with schizophrenia who
displayed elevated CRP had significantly worse working
memory performance. This is consistent with other studies
indicating an association between CRP and cognitive deficits
(such as global cognition, attention/psychomotor speed,
language/executive function, memory, and visual spatial ability)
in other populations including individuals with cardiovascular
disease (75), obstructive sleep apnoea (76), and mild cognitive
impairment (77). Given that BMI also differed between elevated
and normal CRP patient groups in our study, we showed that
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TABLE 11 | Results of regression analysis showing significant contributions of diagnostic (Dx) group (schizophrenia or control), age, sex, and C-Reactive Protein (CRP) to
cortical thickness.
Lobe Brain Region Model Coefficients
R Adjusted R2 (SE) Predictors % Variance Std Beta Coef p FDR
Frontal Frontal pole 0.378 0.115 (0.485) CRP 3.9 −0.199 0.044 0.045
Age 7.4 −0.275 0.006 0.03
Medial orbital frontal 0.538 0.274 (0.319) CRP 7.5 −0.275 0.002 0.016
Age 18.8 −0.435 <0.001 0.005
Lateral orbitofrontal 0.558 0.288 (0.294) CRP 4.1 −0.219 0.021 0.039
Age 9.6 −0.328 0.001 0.015
Diagnosis 4.3 −0.234 0.019 0.036
Superior frontal 0.601 0.34 (0.286) CRP 2.5 −0.170 0.062 0.047
Age 12.3 −0.370 <0.001 0.012
Diagnosis 6.3 −0.283 0.004 0.023
Temporal Temporal pole 0.392 0.135 (0.436) CRP 7.7 −0.279 0.005 0.028
Age 6.1 −0.248 0.012 0.033
Middle temporal 0.610 0.351 (0.285) CRP 3.9 −0.212 0.019 0.037
Age 11.2 −0.353 <0.001 0.006
Diagnosis 6.3 −0.282 0.003 0.021
Entorhinal 0.414 0.153 (0.608) CRP 4.6 −0.231 0.026 0.04
Diagnosis 6.3 −0.270 0.009 0.031
Other Insula 0.666 0.425 (0.269) CRP 5.5 −0.251 0.004 0.024
Age 16.0 −0.419 <0.001 0.014
Diagnosis 5.2 −0.258 0.004 0.024
Paracentral 0.419 0.158 (0.324) CRP 7.4 −0.274 0.005 0.026
Age 8.4 −0.291 0.005 0.026
Only those brain regions showing significant effects are reported in the table.
FIGURE 2 | Brain regions in which C-reactive protein significantly predict
cortical thickness in 51 healthy controls and 41 patients with schizophrenia
using simple linear regressions with backward elimination (regions highlighted
represent significant effects at FDR p < 0.04).
after matching on BMI the significant difference in arithmetic
performance remained between the elevated and normal CRP
patients with schizophrenia; suggesting that factors intrinsic
to schizophrenia and inflammation may underlie the cognitive
deficits in this subgroup of patients. The presence of a significant
difference in cognitive variables between elevated and normal
CRP groups in schizophrenia coupled with the lack of significant
cognitive differences in the healthy sample also supports the
hypothesis suggesting a role of inflammatory processes in
schizophrenia.
In conclusion, the current results show that CRP levels are
substantially elevated in acute psychosis involving the majority of
patients who presented to amental health intensive care inpatient
ward. While we did find some reduction of inflammation across
admissions, we saw continued significantly increased CRP in
these readmitted patients and a lower, but still significant CRP
elevation in chronically ill patients with schizophrenia. NLR
remained significantly elevated in the elevated CRP group of
patients admitted for an acute psychotic episode after covarying
for BMI, suggesting that the elevated inflammation would
not be fully explained by BMI in these acutely ill patients.
Similarly, significant working memory differences remained
between elevated and normal CRP chronically ill patient groups
after covarying for BMI, again suggesting that cognitive deficits
associated with inflammation were not due to elevated BMI.
Importantly, we provide further novel evidence that elevated
CRP is not occurring in isolation of brain changes. We found
significant relationships among peripheral CRP and measures
of human brain structure and function especially involving the
frontal lobe suggesting that this highly evolved human brain
region may be especially sensitive to inflammation. This current
work supports our earlier work (30) on the relationship between
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worse verbal fluency, lower Broca’s area volume and higher IL-
1β levels in patients with schizophrenia, suggesting that anti-
inflammatory drugs may be useful to include as adjunctive
treatments in those patients showing elevated inflammatory
markers (15, 78).
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